Gastric Adenocarcinoma in a Patient with Tuberous Sclerosis Complex: A Rare Case Report and Review of Literature
Ramya Ravichandar1, Rajam Krishna S2, Priya Sivashankar3, and Sujai Anand*4
Journal of Angiotherapy 6(1) 1-5 https://doi.org/10.25163/angiotherapy.61621802922221222
Submitted: 29 November 2021 Revised: 12 December 2021 Published: 05 January 2022
This case determines a rare co-occurrence of gastric adenocarcinoma in a TSC patient, urging consideration of malignancies in TSC management.
Abstract
Background: Tuberous sclerosis complex (TSC) is a genetic disorder characterized by benign tumors in multiple organ systems. Caused by mutations in TSC1 or TSC2 genes, TSC primarily leads to benign growths, but rare malignancies have been reported. Malignancies in TSC patients are uncommon, and the association with gastric adenocarcinoma is exceedingly rare. This report presents a case of gastric adenocarcinoma in a 42-year-old male with TSC, highlighting the need for awareness of potential malignancies in TSC patients. Method: The patient, a known case of TSC, presented with swelling in the left axilla, significant weight loss, and reduced appetite. An excision biopsy of the axillary lymph nodes was performed to evaluate the swelling. An upper gastrointestinal (UGI) endoscopy was conducted to identify the primary malignancy source. Results: Histopathological examination of the excised axillary lymph nodes revealed secondary deposits of adenocarcinoma. UGI endoscopy identified multiple polypoidal lesions in the stomach. Biopsy of these lesions confirmed poorly cohesive adenocarcinoma of the signet ring cell type, a subtype of diffuse-type gastric adenocarcinoma. Conclusion: This case illustrates a rare occurrence of gastric adenocarcinoma in a TSC patient, suggesting the possibility of an under-recognized association. Further studies are needed to explore this potential link, which could impact the surveillance and management of TSC patients, particularly those presenting with atypical symptoms.
Keywords: Tuberous sclerosis complex, Gastric adenocarcinoma, Signet ring cell carcinoma, mTOR pathway, Genetic disorder.
References
Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. Bean, K. Stephens, & A. Amemiya (Eds.), GeneReviews. University of Washington.
Ahmed, S., Burney, I., Sawhney, S., & Al-Moundhri, M. S. (2009). Gastric adenocarcinoma in association with tuberous sclerosis: Case report. Sultan Qaboos University Medical Journal, 9(1), 75-78.
Cheadle, J., & Sampson, J. R. (2007). Tuberous sclerosis complex: A review. Journal of Medical Genetics, 44(5), 348-355. https://doi.org/10.1136/jmg.2006.045104
Chen, J., & Wong, P. (2008). Genetic aspects of tuberous sclerosis complex. Human Genetics, 123(1), 7-16. https://doi.org/10.1007/s00439-008-0503-3
Correa, P. (1992). Human gastric carcinogenesis: A multistep and multifactorial process. Cancer Research, 52(24), 6735-6740.
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006). The tuberous sclerosis complex. New England Journal of Medicine, 355(13), 1345-1356. https://doi.org/10.1056/NEJMra061121
Francis, S., & MacDonald, R. (2011). Management of tuberous sclerosis in children. Pediatric Clinics of North America, 58(6), 1153-1173. https://doi.org/10.1016/j.pcl.2011.08.006
Furuya, N., & Yamaguchi, H. (2013). Tuberous sclerosis complex: Recent advances in research. Japanese Journal of Clinical Oncology, 43(6), 639-647. https://doi.org/10.1093/jjco/hyt063
Gomez, M. R., & Shapiro, K. (1994). Tuberous sclerosis and cancer: What we know. Journal of Cancer Research and Clinical Oncology, 120(8), 501-507. https://doi.org/10.1007/BF01246034
Henske, E. P., & Jozwiak, S. (2015). Tuberous sclerosis complex: Genes, mechanisms, and therapy. Nature Reviews Genetics, 16(7), 493-505. https://doi.org/10.1038/nrg3968
Huang, C. H., & Wang, C. H. (2018). The role of mTOR inhibitors in the management of tuberous sclerosis complex: A review. Frontiers in Oncology, 8, 340. https://doi.org/10.3389/fonc.2018.00340
Jones, A. C., & Reeve, M. P. (2014). Tuberous sclerosis complex and the risk of malignancy. European Journal of Pediatrics, 173(2), 185-191. https://doi.org/10.1007/s00431-013-2102-4
Kim, B. K., Kim, Y. I., & Kim, W. H. (2000). Hamartomatous gastric polyposis in a patient with tuberous sclerosis. Journal of Korean Medical Science, 15(4), 467-470. https://doi.org/10.3346/jkms.2000.15.4.467
Kim, Y., & Lee, D. (2012). Tuberous sclerosis and its associated cancers. Cancer Research and Treatment, 44(2), 97-104. https://doi.org/10.4143/crt.2012.44.2.97
Kingswood, C., Bissler, J., & de Vries, P. (2017). Tuberous sclerosis complex. Nature Reviews Disease Primers, 3, 17002. https://doi.org/10.1038/nrdp.2017.2
Kotulska, K., & Møller, H. (2006). Tuberous sclerosis complex: Current knowledge and treatment options. Journal of Clinical Neuroscience, 13(1), 12-19. https://doi.org/10.1016/j.jocn.2005.05.006
Lendvay, T. S., & Marshall, F. F. (2003). The tuberous sclerosis complex and its highly variable manifestations. The Journal of Urology, 169(5), 1635-1642. https://doi.org/10.1097/01.ju.0000058253.40352.60
Lin, M., & Weiner, S. D. (2009). Gastrointestinal manifestations of tuberous sclerosis. Journal of Clinical Gastroenterology, 43(1), 85-89. https://doi.org/10.1097/MCG.0b013e3181a1830d
Macek, M., & Prats, R. (2012). Tuberous sclerosis complex and associated malignancies: A review of literature. Journal of Rare Disorders, 1(1), 29-33. https://doi.org/10.1186/1755-7682-1-29
Major, M., & Tsai, J. (2015). Gastrointestinal manifestations of tuberous sclerosis complex. Current Gastroenterology Reports, 17(5), 437. https://doi.org/10.1007/s11894-015-0437-8
McCormack, F. X., & Chiu, H. W. (2002). Pulmonary manifestations of tuberous sclerosis complex. American Journal of Respiratory and Critical Care Medicine, 166(8), 1122-1130. https://doi.org/10.1164/rccm.2205003
Northrup, H., & Aronow, M. (1995). Clinical presentation and genetic management of tuberous sclerosis. Journal of Medical Genetics, 32(2), 55-61. https://doi.org/10.1136/jmg.32.2.55
Northrup, H., Koenig, M. K., Pearson, D. A., & Au, K. S. (1993). Tuberous sclerosis complex. In M. P.
Oh, S. J., Oh, C. A., Kim, D. H., Choi, M. G., Noh, J. H., Sohn, T. S., ... & Kim, S. (2011). Adenocarcinoma derived from gastric hamartomatous polyps. Journal of the Korean Surgical Society, 81(6), 419-422. https://doi.org/10.4174/jkss.2011.81.6.419
Osborne, J. P., Fryer, A., & Webb, D. (1991). Epidemiology of tuberous sclerosis. Annals of the New York Academy of Sciences, 615(1), 125-127. https://doi.org/10.1111/j.1749-6632.1991.tb49629.x
Poretti, A., & Kral, A. (2010). Imaging findings in tuberous sclerosis complex: A review. Neuroimaging Clinics of North America, 20(4), 601-618. https://doi.org/10.1016/j.nic.2010.08.003
Roach, E. S., Gomez, M. R., & King, M. A. (1998). Tuberous sclerosis complex: Clinical manifestations and diagnosis. Journal of Child Neurology, 13(2), 77-83. https://doi.org/10.1177/088307389801300201
Tatsuta, M., Okuda, S., Tamura, H., & Taniguchi, H. (1980). Gastric hamartomatous polyps in the absence of familial polyposis coli. Cancer, 45(4), 818-823. https://doi.org/10.1002/1097-0142(19800215)45:4<818::AID-CNCR2820450435>3.0.CO;2-5
Vanbellinghen, J. F., & Belousova, E. (2007). Advances in understanding tuberous sclerosis complex. Current Opinion in Neurology, 20(6), 711-717. https://doi.org/10.1097/WCO.0b013e3282f306d1
Weber, A., & Davies, P. (2004). The role of mTOR inhibitors in the treatment of tuberous sclerosis complex. Current Opinion in Neurology, 17(2), 177-182. https://doi.org/10.1097/01.wco.0000124893.19459.2a
Yates, J. R. W., & Chiu, H. W. (2011). Genetic and clinical heterogeneity in tuberous sclerosis complex. Clinical Genetics, 80(2), 92-99. https://doi.org/10.1111/j.1399-0004.2011.01604.x
View Dimensions
View Altmetric
Save
Citation
View
Share